24 May 2016 AIM: REDX REDX PHARMA PLC (“Redx” or “Company ...€¦ · Redx Pharma plc INTERIM...

of 19

24 May 2016 AIM: REDX

REDX PHARMA PLC

(“Redx” or “Company” or “Group”)

Interim Results

Redx (AIM: REDX), the drug discovery and development company, is pleased to announce its unaudited interim results for the six months ended 31 March 2016.

HIGHLIGHTS

Continued strong progress across proprietary research programs

Oncology pipeline - fourth development candidate selected – Porcupine inhibitor for hard-to-treat cancers,

such as pancreatic, triple negative breast and head and neck cancers

- post period: in vivo proof of concept achieved in BTK program – reversible inhibitor with potential to treat leukaemia and other blood cancers – see separate announcement issued today

Anti-infectives pipeline - proof of concept established with a lead compound which has the potential to treat

gonorrhoea, one of the most common sexually transmitted infections globally

Immunology pipeline - several projects have now been successfully initiated - currently conducting pre-clinical efficacy studies for treatment of an immunological

disease with high unmet need

H1 financial results in line with management expectations: - net cash at 31 March 2016: £4.4m (H1 2015: £13.8m) - comprehensive loss of £7.1m (H1 2015: £3.2m)

Successful share placing to raise £10m (gross) completed in April, after period end

Outlook remains positive and the Company remains well-positioned to secure value from its assets and to further develop the business

Redx Pharma plc

INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 MARCH 2016

of 19

Neil Murray, Chief Executive of Redx Pharma Plc, said: “I am pleased to report that interim results are in line with management expectations and that Redx’s innovative pipeline has made excellent progress over the period. We identified a fourth drug development candidate, a Porcupine inhibitor, which has the potential to tackle hard-to-treat cancers, such as pancreatic, triple negative breast and head and neck cancers, reaching development stage in less than two years, significantly ahead of industry averages. Our anti-infectives team also achieved a further proof of concept, with a lead which has the potential to treat drug-resistant gonorrhoea. Today, we are delighted to announce our seventh proof of concept, a BTK reversible inhibitor that has the potential to treat leukaemia and other blood cancers. We completed a £10m fundraise shortly after the period ended, which leaves us well-positioned to build on our pipeline progress and grow the business.” For further information, please contact:

Redx Pharma Plc T: 0151 706 4747

Neil Murray, Chief Executive

Company website: redxpharma.com

Cantor Fitzgerald Europe (Nomad & Broker) T: 020 7894 7000

Phil Davies / Michael Reynolds

KTZ Communications T: 020 3178 6378

Katie Tzouliadis/ Viktoria Langley/ Emma Pearson

Redx Pharma plc


of 19

About Redx Pharma Plc

www.redxpharma.com

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to

address areas of high unmet medical need, principally in cancer, infection and immunology, providing

a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug

classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a

portfolio of proprietary (patent-protected) drug programs. Seven proof of concepts have been

achieved, with relevance for respective therapies to treat MRSA, Gonorrhoea, bone tumours, skin,

brain, breast, pancreatic and blood cancers.

http://www.redxpharma.com/

Redx Pharma plc


of 19

Redx Pharma plc


of 19

ImbruvicaTM (ibrutinib), which is an .

Redx Pharma plc


of 19

- - - -

- -

Redx Pharma plc


of 19

Redx Pharma plc


of 19

http://redxpharma.com/investors.html

24 May 2016 AIM: REDX REDX PHARMA PLC (“Redx” or “Company ...€¦ · Redx Pharma plc INTERIM...

Documents

Transcript of 24 May 2016 AIM: REDX REDX PHARMA PLC (“Redx” or “Company ...€¦ · Redx Pharma plc INTERIM...